Gilead to acquire oral IL-23R inhibitor for $1.28 billion
Gilead Sciences (GILD) agreed to acquire an oral IL-23R inhibitor program from PepStar Therapeutics for $1.28 billion in cash. The deal includes HCXT-2001, a Phase 1 drug for inflammatory diseases. Gilead expects the transaction to close in Q4 2026, reducing its EPS by $0.79-$0.83. PepStar is a private biotech company.
How this was made
The 30-second read
Why it matters
The deal is material, reduces near‑term earnings, and signals Gilead's strategic shift toward oral therapies in immunology.
Market read
Primary M&A news with immediate pricing impact for GILD; no other listed entities are subjects.
What to watch
Potential synergies with Gilead's existing inflammation pipeline and future combination benefits.
Background
Gilead is expanding its inflammation pipeline with an oral macrocyclic peptide targeting IL‑23R, a validated target for IBD and psoriasis.
Ticker impact
Gilead Sciences announced a definitive agreement to acquire PepStar Therapeutics' oral IL-23R inhibitor program for $1.275 billion, impacting its Q4 2026 earnings per share.
likely downward pressure as the market prices in the EPS dilution and large cash outflow.
Large cash deal and explicit EPS reduction guidance are material and new, prompting traders to reassess valuation.
Market effects
Adds to consolidation in the biotech inflammation space, may spur competitor M&A activity.
US biotech sector could see modest pullback due to the sizable cash outlay.
Limited to biotech investors; no broad market effect expected.
Counterpoint
The oral IL‑23R program could unlock a high‑margin franchise, offsetting short‑term EPS hit.
Key entities
- companyGilead Sciences, Inc.
US‑listed biopharma acquiring the IL‑23R program.
- companyPepStar Therapeutics Limited
Private biotech selling its oral IL‑23R inhibitor program.